Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

University of Southern California researchers have found a way to rebrand this oft-embarrassing sore subject by genetically ...

Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 2018;19:672-681.

Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-330. Crossref. PubMed. Web of Science. Google Scholar. 24.

Nivolumab treatment in melanoma patients has manageable safety profile. ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2015 / 05 / 150528153517.htm ...

The herpes simplex virus type 1 (HSV-1), which affects almost two‑thirds of the world's population and is generally ...

A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma ...

Scientists are developing all sorts of potential new treatments to tackle the most difficult cancer cases—including some that ...

Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402) Thirty-five patients were ...

THURSDAY, Sept. 19, 2024 (HealthDay News) -- For patients with advanced melanoma, there is a survival benefit for nivolumab plus ipilimumab and for nivolumab monotherapy compared with ipilimumab ...